Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879832 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5392232 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL6056281 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5406229 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5529607 | 1.00 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL14459057 | 0.91 | CYP1A2 (0.50) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL7432467 | 0.89 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL23355288 | 0.88 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL2592513 | 0.88 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL5388086 | 0.88 | CYP1A2 (0.53) | CYP1A2ALDH1A1USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1514541-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | Warner-Lambert Company LLC (US) | 2005-03-16 | — | — | EP | claimed |
| EP-1506955-A1 | Bicyclic amino acids as pharmaceuticals agents | Warner-Lambert Company LLC (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | CHOVET MARIA (FR) | 2004-12-30 | — | — | US | claimed |
| US-6784208-B2 | BICYCLIC FUSED HYDROCARBON RINGS SUBSTITUTED WITH AMINOMETHYL AND CARBOXYMETHYL GROUPS ON SAME POSITION OF RING; 3-AMINOMETHYL-BICYCLO(3.2.0)HEPTANE-3-ACETIC ACID FOR EXAMPLE | WARNER-LAMBERT COMPANY | 2004-08-31 | — | — | US | claimed |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2004-08-05 | — | — | US | claimed |
| JP-2004517147-A | — | — | 2004-06-10 | — | — | JP | claimed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | claimed |
| US-6689906-B1 | Bicyclic amino acids as pharmaceutical agents | WARNER-LAMBERT COMPANY | 2004-02-10 | — | — | US | claimed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | claimed |
| EP-1357910-A2 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | Warner-Lambert Company LLC (US) | 2003-11-05 | — | — | EP | claimed |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002058680-A2 | USE OF BICYLIC AMINO ACIDS FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1226820-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| EP-1226110-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2001028978-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-04-26 | — | — | WO | claimed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001028978-A1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | CYP1A2 347/4885ALDH1A1 268/4885USP2 4327/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CYP1A2 1403/4885ALDH1A1 30/4885USP2 1071/4885 |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | CYP1A2 845/4885ALDH1A1 420/4885USP2 3321/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CYP1A2 1403/4885ALDH1A1 30/4885USP2 1071/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | CYP1A2 272/4885ALDH1A1 104/4885USP2 2142/4885 |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | CYP1A2 845/4885ALDH1A1 420/4885USP2 3321/4885 |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | AADAT, SLC1A2, BCAT1 | CYP1A2 1081/4885ALDH1A1 1224/4885USP2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.